8 Jun 2022
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC
Author: admintech | Filed under: Press ReleaseJERUSALEM, June 8, 2022 /PRNewswire/ — Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved…